Status:
COMPLETED
Feasibility of Immunotherapy Administration to Patients With Bronchial Cancer in a Hospital-at- Home Setting (ImHADom)
Lead Sponsor:
RENAULT Patrick Aldo
Conditions:
Bronchial Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This observational prospective monosite study aims to describe, for the first time, management in a hospital-at-home programme of patients treated by immunotherapy for bronchial cancer. The feasibili...
Detailed Description
Those last years, immunotherapy treatment for bronchial cancers allowed considerable progress in terms of tumoral answer, survival without progression and global survival. Usually administered in the ...
Eligibility Criteria
Inclusion
- Patients aged 18 and over.
- with bronchial cancer treated with immunotherapy,
- having two assessments of the response to immunotherapy received in day hospitalization with efficiency (stability or partial response)
- without any graded higher than 1 adverse effects, or uncontrolled grade 1 adverse effects related to immunotherapy
- eligible for a home-based hospitalization
Exclusion
- Patient receiving immunotherapy via temporary authorization for use,
- Frail patients requiring a frequent medical assessment thus day hospitalization cares
Key Trial Info
Start Date :
March 6 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 6 2020
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT03786653
Start Date
March 6 2019
End Date
December 6 2020
Last Update
September 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre hospitalier de pau
Pau, Aquitaine, France, 64160